Literature DB >> 11601502

Metabolic changes following subthalamotomy for advanced Parkinson's disease.

P C Su1, Y Ma, M Fukuda, M J Mentis, H M Tseng, R F Yen, H M Liu, J R Moeller, D Eidelberg.   

Abstract

We studied 6 advanced-stage Parkinson's disease patients with [18F] fluorodeoxyglucose/positron emission tomography before and 3 months after unilateral ablation of the subthalamic nucleus performed with microelectrode mapping. Operative changes in glucose metabolism were assessed by comparing baseline and postoperative scans. We also quantified operative changes in the activity of an abnormal Parkinson's disease-related metabolic network that we had identified in previous [18F] fluorodeoxyglucose/positron emission tomography studies. Following unilateral subthalamic nucleus ablation, a highly significant reduction in glucose utilization was present in the midbrain ipsilateral to the lesion site, most pronounced in the vicinity of the substantia nigra pars reticularis. Significant metabolic reductions were also present in the ipsilateral internal globus pallidus, ventral thalamus, and pons. Operative changes in Parkinson's disease network activity differed significantly for the lesioned and unlesioned hemispheres. In the lesioned hemisphere, network activity declined significantly following surgery, but was unaltered in the contralateral, unlesioned hemisphere. These results suggest that subthalamotomy reduces basal ganglia output through internal globus pallidus/substantia nigra pars reticularis and also influences downstream neural activity in the pons and ventral thalamus. This procedure also reduces the activity of abnormal Parkinson's disease-related metabolic brain networks, suggesting a widespread modulation of motor circuitry.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11601502     DOI: 10.1002/ana.1232

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  20 in total

Review 1.  The assessment of neurological systems with functional imaging.

Authors:  David Eidelberg
Journal:  Brain Lang       Date:  2006-08-08       Impact factor: 2.381

2.  Network modulation in the treatment of Parkinson's disease.

Authors:  Kotaro Asanuma; Chengke Tang; Yilong Ma; Vijay Dhawan; Paul Mattis; Christine Edwards; Michael G Kaplitt; Andrew Feigin; David Eidelberg
Journal:  Brain       Date:  2006-07-14       Impact factor: 13.501

3.  Assessment of disease progression in parkinsonism.

Authors:  Kotaro Asanuma; Vijay Dhawan; Maren Carbon; David Eidelberg
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

4.  Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease.

Authors:  Jian Wang; YiLong Ma; ZheMin Huang; BoMin Sun; YiHui Guan; ChuanTao Zuo
Journal:  J Neurol       Date:  2009-08-07       Impact factor: 4.849

Review 5.  Metabolic networks for assessment of therapy and diagnosis in Parkinson's disease.

Authors:  Shigeki Hirano; Thomas Eckert; Toni Flanagan; David Eidelberg
Journal:  Mov Disord       Date:  2009       Impact factor: 10.338

6.  Functional impact of subthalamotomy by magnetic resonance-guided focused ultrasound in Parkinson's disease: a hybrid PET/MR study of resting-state brain metabolism.

Authors:  Rafael Rodriguez-Rojas; Jose A Pineda-Pardo; Raul Martinez-Fernandez; Rosalie V Kogan; Carlos A Sanchez-Catasus; Marta Del Alamo; Frida Hernández; Lina García-Cañamaque; Klaus L Leenders; Jose A Obeso
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-08       Impact factor: 9.236

7.  Contribution of decreased serotonin release to the antidyskinetic effects of deep brain stimulation in a rodent model of tardive dyskinesia: comparison of the subthalamic and entopeduncular nuclei.

Authors:  Meaghan C Creed; Clement Hamani; Alanna Bridgman; Paul J Fletcher; José N Nobrega
Journal:  J Neurosci       Date:  2012-07-11       Impact factor: 6.167

8.  Covariance PET patterns in early Alzheimer's disease and subjects with cognitive impairment but no dementia: utility in group discrimination and correlations with functional performance.

Authors:  Nikolaos Scarmeas; Christian G Habeck; Eric Zarahn; Karen E Anderson; Aileen Park; John Hilton; Gregory H Pelton; Matthias H Tabert; Lawrence S Honig; James R Moeller; Davangere P Devanand; Yaakov Stern
Journal:  Neuroimage       Date:  2004-09       Impact factor: 6.556

9.  Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease.

Authors:  Maja Trost; Sherwin Su; Philip Su; Ruoh-Fang Yen; Ham-Min Tseng; Anna Barnes; Yilong Ma; David Eidelberg
Journal:  Neuroimage       Date:  2006-02-08       Impact factor: 6.556

10.  Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease.

Authors:  Andrew Feigin; Michael G Kaplitt; Chengke Tang; Tanya Lin; Paul Mattis; Vijay Dhawan; Matthew J During; David Eidelberg
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.